Background: Primary central nervous system lymphoma (PCNSL) remains an aggressive and refractory tumor despite high-dose methotrexate-based chemo-radiotherapy. Age and performance status have been shown to be important clinical prognostic factors, however others, especially molecular factors, affecting the prognosis are still uncertain. Methods: We investigate clinical, neuroimaging and immunohistochemical data in tissue from 41 PCNSL patients treated primarily with methotrexate-based chemo-radiotherapy and evaluate the influence of potential prognostic factors on clinical outcome as well as correlation among these factors. Results: Median progression-free survival (PFS) and overall survival (OS) were 29 and 73 months, respectively. Expression of the mismatch repair (MMR) proteins, MLH1, MSH2, MSH6 and PMS2, correlated tightly with each other and high expression of MSH2 was significantly associated with better OS and PFS (P = 0.005 and P = 0.007), while methotrexate metabolism-related proteins did not affect survival. In addition, low expression of PMS2 was an independent predictor of methotrexate resistance (P = 0.039). Among neuroimaging findings, involvement of the fornix and tegmentum/velum were significantly associated with poorer OS (P < 0.001 and P = 0.013) and PFS (P = 0.014 and P = 0.043, respectively). Germinal center B cell (GCB)-PCNSL subtype as opposed to non-GCB subtype, tended toward better survival. Regarding oncogenes, cMYC-positive cases showed unfavorable OS (P = 0.046). By multivariate analysis, MSH2 and involvement of the fornix were independent predictors for both OS and PFS, whereas tegmentum/velum location and cMYC expression were significantly associated with OS. Conclusions: Although further studies are needed, these results suggest that MMR protein expression, as well as specific deep locations and cMYC expression, may be a novel prognostic and predictive markers for PCNSL.
Introduction
Primary central nervous system (CNS) lymphoma (PCNSL) is an aggressive malignant tumor affecting the brain, spinal cord, meninges and eyes. PCNSL is an uncommon disease representing 3.5% of all primary CNS tumors and 1% of all lymphomas, and has shown an increasing incidence in recent decades (1, 2) . Although PCNSL belongs to the extranodal non-Hodgkin lymphomas and~95% of PCNSL is the diffuse large B-cell lymphoma (DLBCL), its aggressive clinical course is different from that of systemic DLBCL (3, 4) . Highdose methotrexate (HD-MTX) therapy is recognized as the most effective chemotherapy and HD-MTX based chemotherapy with or without radiotherapy has been standardized approach to the treatment of PCNSL (5, 6) . PCNSL prognosis has improved over the past decade with complete remission rates of 35-79% and median overall survival (OS) of 31-79 months (5, 7, 8) .
Many studies on the prognosis of PCNSL reported that age and performance status (PS) were significant clinical factors and were accepted as prognosticators (9) (10) (11) . However, whether other clinical factors, such as tumor location, multiplicity, lactate dehydrogenase (LDH) level, cerebrospinal fluid (CSF) protein concentration and the extent of resection, may also affect PCNSL prognosis has been uncertain (9) (10) (11) (12) . In addition, studies of molecular factors that might be associated with prognosis have not been fully investigated in PCNSL.
Recent studies in malignant tumors demonstrated that several molecular factors have been involved in prognosis and thus could be specific therapeutic targets. Systemic DLBCL could be classified into the subtypes of germinal center B cell (GCB) and non-GCB by expression of cell markers and patients with GCB-DLBCL showed a better survival than those with non-GCB-DLBCL (13) (14) (15) (16) . Other studies have suggested a link between expression of oncogenic proteins such as cMYC, BCL2 and STAT3 and unfavorable prognosis in malignant tumors, including DLBCL (17) (18) (19) . Drug resistance system components have also been associated with prognosis in some malignant tumors. Multidrug resistance related protein (MRP) and lung resistance related protein (LRP) are such components, which act as drug efflux pumps, decreasing intracellular drug concentrations (20) (21) (22) (23) . Furthermore, DNA repair systems, including O 6 -methylguanine-DNA methyltransferase (MGMT) and mismatch repair (MMR), have been implicated in resistance to chemo-radiotherapy in glioblastoma (24) (25) (26) .
In the current study, we investigated clinical, neuroimaging and immunohistochemical findings of PCNSL patients treated primarily with HD-MTX-based chemo-radiotherapy and evaluated the influence of potential prognostic factors on clinical outcome and correlation among these factors.
Patients and methods

Study population
Immunocompetent patients with PCNSL who were treated in our institution since 2000-13 and whose tumor tissues were available for immunohistochemical analyses were retrospectively investigated. All patients were diagnosed histopathologically as DLBCL without evidence of systemic lymphoma. They were primarily treated with HD-MTX based chemo-radiotherapy. This study was approved by the ethical review board of Kyorin University Faculty of Medicine, with written consent obtained from each patient.
Clinical information and response evaluation
The following clinical factors were used in the current study: age, gender, Karnofsky Performance Status (KPS), serum LDH, number of lesions, presence of meningeal dissemination and tumor location if deep lesions (periventricular regions, basal ganglia, brainstem or cerebellum), as well as the anterior fornix or tegmentum/velum, are involved. Treatment response was determined by magnetic resonance imaging (MRI) based on the International PCNSL Collaborative Group Criteria and classified as follows: complete response (CR; complete disappearance of all enhancing abnormalities), partial response (PR; 50% decrease in the contrast-enhancing lesion), progressive disease (PD; 25% increase in the contrast-enhancing lesion or the appearance of a new lesion) or stable disease (SD; neither PR nor PD) (27) .
Immunohistochemistry
Immunohistochemical staining was done using the enzyme-labeled antibody method. Formalin-fixed, paraffin-embedded tissue blocks were cut in 3 μm sections. The sections were deparaffinized in xylene, rehydrated using a graded series of ethanol solutions, blocked with 0.06-3% hydrogen peroxide for 10-30 min, and appropriately retrieved. The sections were incubated with peroxidase-blocking solution or normal goat serum (Dako, Glostrup, Denmark) and then incubated with primary antibodies at 4°C overnight. After wash, the sections were incubated with a peroxidase-conjugated EnVision polymer and anti-rabbit or antimouse secondary antibodies (Dako) for 30 min at room For each immunostaining, three randomized sites were selected (at least 1000 cells for each slide) under a high-power microscope and the percentage of positive cells was recorded. The data were analyzed to determine statistically the optimal cutoff points for discriminating positive and negative: we used the cutoff of 30% for CD10, BCL6 and MUM1 according to previously published criteria (15), while we determined the proper cutoff points with a receiver operating characteristic (ROC) curve for other protein expressions, because there are no established cutoff values for expression rates in these proteins in the literature and their rates vary substantially from a protein to anther, necessitating setting the new cutoff lines for each molecule. All cases were sub-classified into GCB type and non-GCB type according to Hans algorithm (15) , and as GCB type and activated B cell (ABC) type according to Choi algorithm (14) .
Statistical analysis
Survival analysis was performed using the Kaplan-Meier method. OS was defined as the time from diagnosis until death or last follow-up visit, while progression-free survival (PFS) was defined as the time from diagnosis until disease progression, recurrence, death or last follow-up visit. The log-rank test was used for univariate analysis, and then the Cox proportional hazards model was used for multivariate analysis using variables with P < 0.2 on univariate analysis. The Fisher's exact test and Spearman's rank correlation were used to determine association and correlation among variables. All variables with P < 0.05 were considered to be statistically significant. These statistical analyses were performed using IBM SPSS version 20.0 software.
Results
Patient characteristics
Forty-one patients (25 males, 16 females) were enrolled in the current study (Table 1) . Their mean age was 62.8 years (range 19-84) and median KPS was 60 (range 30-100). Multifocal lesions were found in 28 cases (68%), and 30 cases (73%) had involvement of the deep lesions including the anterior fornix (10 cases, 24%) and the tegmentum/velum (five cases, 12%). Ten cases (24%) had meningeal dissemination. An elevated LDH serum level (>220 IU/L) was detected in 17 cases (45%).
More than half of the cases underwent biopsy (23 cases), while resection was performed in the others. All but three cases (93%) were treated with HD-MTX therapy as an induction treatment, including those (17%) combined with rituximab, procarbazine and vincristine (R-MPV therapy). WBRT was performed in 38 cases (93%) using the dose of 24-40 Gy with or without local boost. Seven cases were also treated with high-dose AraC (cytarabine) as a consolidation therapy.
Immunohistochemical profiles and correlation among factors
To investigate molecular markers for PCNSL, we performed a series of immunohistochemical analyses in 41 cases using specific antibodies as shown in Fig. 1 . The cutoff values and positivity rates are summarized in Table 2 . According to the Hans algorithm (15), eight (20%) were considered as GCB type, while 33 (80%) as non-GCB type. When the Choi algorithm was applied (14) , 12 of 39 (30%) were considered as GCB type and the others (70%) were considered as ABC type. The association between GCB subtype and molecular factors was listed in Table 3 . GCB subtype was significantly correlated with p27 high expression (P = 0.014).
By correlation analysis of expression among molecular factors, there were significantly positive associations between Ki67 and oncogenes (BCL2, cMYC or pSTAT3), and among oncogenes (BCL2 and pSTAT3; cMYC and pSTAT3). Similarly, there were significant correlations between Ki67 and BCL6, MUM1 or MSH2, and among these proteins (BCL6 and MSH2; MUM1 and MSH2) as well. Furthermore, MMR proteins; MLH1, MSH2, MSH6 and PMS2 showed strong positive correlations between each other (Table 4) .
Clinical and molecular factors associated with survival
Of all cases except three with gross total resection, 31 (82%) and seven (18%) cases achieved a CR and a PR, respectively, after induction chemo-radiotherapy. However, 20 cases had disease progression and recurrence during follow-up, and then 17 cases were treated with additional chemotherapy, while 14 cases received reirradiation. The median PFS was 29 months and the median OS was 73 months.
The univariate analysis for clinical factors showed that younger age (<60 years) at diagnosis was associated with poorer OS and PFS in this study (P = 0.005 and P = 0.002, respectively) ( Table 5) . Although the deep lesions did not affect survival, involvement of the anterior fornix or tegmentum/velum was significantly associated with poorer OS (P < 0.001 and P = 0.013, respectively) and PFS (P = 0.014 and P = 0.043, respectively) (Fig. 2) . Patients with meningeal dissemination or multiple lesions tended to have shorter survival, but this was not statistically significant. Extent of resection did not affect outcome (P = 0.099 for OS and P = 0.202 for PFS).
Regarding molecular and differentiation markers, OS and PFS tended to be longer in BCL6-positive cases (P = 0.055 and P = 0.051, respectively). Patients with GCB subtype also had a tendency toward better survival, but this was not statistically significant (P = 0.139 and P = 0.167, respectively). Those with positive expression of p27, a cyclin-dependent kinase inhibitor, had a slightly longer PFS, but this was also not statistically significant (P = 0.189). High expression of a lymphoma-related oncogene, cMYC, was significantly associated with poor OS (P = 0.046). Co-expression of cMYC and BCL2 was observed in 11 cases (27%), with significantly inferior OS (29.7 months, 95% confidence interval 4.0-55.5) to those without (73.3 months, 95% confidence interval 55.4-91.2) (P = 0.045). Notably, both OS and PFS were significantly better in patients with higher expression of MMR proteins: MLH1 (P = 0.010 and P = 0.024, respectively), MSH2 (P = 0.005 and P = 0.007, respectively) (Fig. 2) . Expression of other MMR proteins also tended to be associated with better outcome (OS/PFS, P = 0.047/0.183 for MSH6; P = 0.124/ 0.206 for PMS2). Multivariate Cox proportional hazards analysis for OS showed that involvement of the anterior fornix (P < 0.001), tegmentum/ velum (P = 0.001) and cMYC expression (P = 0.018) were significant unfavorable predictors, whereas MSH2, as a representative of MMR proteins, was a significant favorable predictor (P = 0.001), when age was unadjusted. Even with age-adjusted analysis, the fornix (P < 0.001) and MSH2 (P = 0.034) remained significant predictors for OS. Similarly, the involvement of the anterior fornix (P = 0.036) and MSH2 (P = 0.003) were significantly associated with PFS (Table 5 ).
Response to methotrexate
Among 31 cases who were treated with HD-MTX monotherapy prior to radiotherapy, excluding those treated with multidrug therapy or radiotherapy only, 12 cases had early disease progression or recurrence during HD-MTX therapy (Table 6 ). We investigated whether any factors were associated with MTX resistance among MTX metabolism-related proteins (DHFR, MRP1 and LRP) and DNA repair proteins (MGMT, MLH1, MSH2, MSH6 and PMS2). There was a significant correlation between MTX resistance and lower expression of PMS2 (P = 0.039, multivariate logistic regression analysis).
Discussion
PCNSL has yet been a refractory and lethal brain tumor despite initial sensitivity to chemo-radiotherapy, necessitating investigation of factors associated with early relapse and drug resistance. In the current study, 31 (82%) cases achieved a CR after induction therapy, however 20 of these relapsed and followed aggressive courses, regardless of salvage therapies including additional chemo-and/or radiotherapy. Here we show that among clinico-molecular factors evaluated, higher expression of MMR proteins was strongly associated with better outcome of PCNSL patients, and to the best of our knowledge, this is the first report to investigate the relation between MMR proteins and PCNSL prognosis. In addition, specific deep locations, GCB subtype and oncogene expression affected survival, but MTX metabolism-related proteins did not.
MMR pathways play important roles to maintain DNA replication by repairing DNA mismatches such as base mismatches or insertion-deletion loops (28) . Thus, loss of MMR functions causes a high mutation rate and microsatellite instability, leading to cancer development (28) (29) (30) . Resistance to treatment could also be associated with this pathway, because most chemotherapy and radiotherapy induces DNA destabilization (31, 32) . Some clinical studies demonstrated that a reduced expression of MMR proteins was associated with poor prognosis in hereditary nonpolyposis colorectal carcinoma, endometrial carcinomas, and soft tissue tumors (33) (34) (35) . In our PCNSL study, lower expression of MMR proteins were significantly associated with shorter PFS and OS. Additionally, a lower expression of PMS2 was significantly involved in MTX resistance, suggesting that the MMR pathway could play an important role in preventing tumor progression and MTX resistance in PCNSL. B-cell development is composed of complicated and diverse processes, which employ genome rearrangement with modification by somatic hypermutation and class switch recombination through several stages (36) . Furthermore, PCNSL is a highly proliferative tumor (37) where DNA mismatches could be expected. MMR proficient cells could recognize such lesions and either repair the errors, or if not repairable, induce apoptosis to maintain DNA replication. In contrast, in MMR deficient cells, the damaged mismatched DNA could The correlation between expressions of IHC markers was assessed using Spearman's rank correlation analysis and significant correlation coefficients and P values* are indicated in bold.
not be sensed and repaired, resulting in accumulation of microsatellite instability, thereby leading to treatment resistance and disease progression (29, 38, 39) . In this sense, the MMR system may be required for preventing a poor outcome, especially in PCNSL.
Neuroimaging could potentially be a prognostic tool. The International Extranodal Lymphoma Study Group reported involvement of the deep structures of the brain, which included periventricular regions, basal ganglia, brainstem and cerebellum (10), as having prognostic significance. In a nationwide survey of 466 patients treated at 62 Japanese institutions, the number of lesions and the presence of meningeal dissemination were related to survival in PCNSL (11) . However, it is yet unclear which imaging features are the most relevant to prognosis (40) (41) (42) . Recently, Kinoshita et al. reported a correlation between specific location at either the upper tegmentum and superior medullary velum, or anterior fornix with GCB subtypes in PCNSL (43) . In the present study, there was no apparent correlation between the spatial distributions and subtypes, but rather a significant association of the involvement of the anterior fornix and tegmentum/velum, but not deep locations, with poorer survival was found. Although these specific locations may enhance the risk of performance deterioration affecting cognitive and brainstem functions and might be less accessible for drugs, further studies are needed to confirm this relationship.
Given that nearly all PCNSL is DLBCL, GCB typing may be a prognosticator of PCNSL as many studies have demonstrated a better prognosis in GCB subtype than in non-GCB in systemic DLBCL (13) (14) (15) (16) . Accordingly, most studies including our previous report (44) have shown that GCB subtype is associated with favorable prognosis in PCNSL (40, 41, 45) , and we also found a similar tendency of better survival in GCB subtype to some extent. Our study also demonstrated that GCB subtype correlated with high expression of p27 protein. p27 protein is a negative regulator of cell cycle at G1-to S phase transition and high p27 expression is indicative of better outcome in DLBCL (46) . This correlation supports that GCB subtype have potentially better survival than non-GCB subtype. Rather, positive BCL6 expression appears to be associated with favorable outcome, however, there has been considerable controversy over the prognostic role of BCL6 in PCNSL (6, 42, 45, (47) (48) (49) (50) . One of the reasons for this discrepancy is that there was only one prospective study assessing the prognostic value of BCL6 expression in a small number of cases (6) . Most other retrospective studies also have limitations with sample size, patient selection bias, as well as nonuniform treatment schedules, using different antibody clones and evaluation methods for BCL6 detection among the studies (42, 49, 50) . Indeed, BCL6 was not selected as an independent marker by multivariate analysis. Further studies are clearly needed OR; odds ratio. to justify the significance of using GCB subtyping or BCL6 expression as a prognosticator for PCNSL including whether cell-of-origin determination by gene expression profiling (51) may be superior to immunohistochemical testing for the classification. Expression of oncogenic proteins, cMYC, STAT3 (cellular proliferation promoters) and BCL2 (cell death inhibitor), were also shown to be unfavorable predictors in systemic DLBCL (17) (18) (19) . In PCNSL, however, only a few studies concerning the relationship between expression of these proteins and survival have been reported. Chang et al. reported that cMYC was expressed in 50% of PCNSL patients, whose survival was poorer than those without (47) . BCL2 expression was found in 49-89% of PCNSL cases, however there was no relation with prognosis (40, 41, 45, 47, 48) . In this study, expression of these oncogenes correlated well with proliferative activity, and high cMYC expression was significantly associated with poor OS. In addition, coexpression of cMYC and BCL2 was also a significant unfavorable indicator for OS, in agreement with the recent observation in systemic DLBCL showing strong association with inferior survival (18, 52, 53) , perhaps because this double positivity would confer synergistic effects of both promoting proliferation and anti-apoptosis. The role of additional, recently identified hallmark genetic alterations such as MYD88 and Grb2 (44) on PCNSL prognosis is underway in a newer cohort.
Regarding the role of surgery for PCNSL, biopsy has generally been recommended because PCNSL is extensively infiltrative through perivascular space into brain parenchyma, and often develops multiple and deep-seated lesions (2, 10, 42) . More importantly, HD-MTX based chemotherapy with or without radiotherapy is highly effective in inducing complete response leading to improved survival (5, 7, 8) . Aggressive surgical resection is applied only if there is a considerable tumor-derived mass effect causing serious neurological and conscious deteriorations that could be relieved by mass reduction, thereby allowing the patient to readily receive remission inducing chemotherapy (54) . Accordingly, extent of resection was not a significant predicator for survival by multivariate analysis in our study. Recently, Weller et al. reported that patients with total or partial resection had a longer PFS and OS than those with biopsy in a post-hoc analysis of prospective randomized trial G-PCNSL-SG-1 (12), thus shedding light on the role of resection at least when performed safely for a single lesion.
Since a long-term survival has not been sufficiently achieved by HD-MTX alone, multi-agent HD-MTX based combination therapies have been intensively explored with reduced dose WBRT or even without WBRT in prospective trials. These include a combination of rituximab, HD-MTX, procarbazine, and vincristine, followed by consolidating high-dose cytarabine (R-MPV-A), rituximab with HD-MTX and temozolomide (MT-R) followed by etoposide and cytarabine consolidation, and rituximab, HD-MTX, cytarabine, and thiotepa combination (MATRix) with high dose chemotherapy with stem cell rescue or WBRT, all of which resulted in high survival rates without causing neurotoxicity (5, 6, 55) . Thus we also implemented using rituximab on the top of MPV regimen since 2012, including seven cases in the current study, after using HD-MTX alone since 2000. Currently we treat patients with newly diagnosed PCNSL using the R-MPV-A regimen, and prognostic analyses in this cohort of uniformly treated patients will be pursued.
We observed that younger age (<60 years) at diagnosis indicated poor prognosis, which conflicts with previous reports (9, 10) . This discrepancy may be potentially related to the limitations of our present study; a small sample size, non-uniform treatments and retrospective single-institutional analysis. There were only four (10%) patients younger than 50 years, the Class 1 in MSKCC score would be expected to have the best prognosis, but they actually had quite a short survival (median OS 6.9 months). Recent cases from 2008 to 2013 included a high percentage of patients older than 60 years and some of them have remained progression-free and achieved longer survival. Although most patients received HD-MTX and WBRT, treatment intensity has also increased in recent cases (including seven cases with R-MPV, and of six cases over 60 years old). Taken together, ageassociated prognosis was substantially confounded in this study, and thus removed from analyses. However, even when age is incorporated in multivariate analysis, the prognostic value of both involvement of the fornix and MSH2 expression remained significant.
In conclusions, this clinico-molecular study disclosed that low expression of MMR proteins was significantly associated with poor prognosis and MTX resistance in PCNSL and this is the first demonstration of potential implication of MMR in PCNSL. The involvement of the anterior fornix and tegmentum/velum, and cMYC expression were also correlated with shorter OS, whereas BCL6 high expression tended to be a better prognosticator. Further studies using a larger patient population with homogeneous treatment protocols, such as clinical trials, are needed to confirm the significance of these findings.
